The UPMC Hillman Cancer Center, previously titled the University of Pittsburgh Cancer Institute, is a National Cancer Institute-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States, adjacent to UPMC Shadyside.

During the past decade, UPMC Hillman Cancer Center conducted 311 clinical trials. In the 10-year time frame, 311 clinical trials started and 137 clinical trials were completed, i.e. on average, 44.1% percent of trials that started reached the finish line to date. In the past 5 years, 167 clinical trials started and 70 clinical trials were completed. i.e. 41.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC Hillman Cancer Center" #1 sponsor was "University of Pittsburgh" with 46 trials, followed by "Bristol-Myers Squibb" with 21 trials sponsored, "Eastern Cooperative Oncology Group" with 18 trials sponsored, "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins" with 18 trials sponsored and "Pfizer" with 18 trials sponsored. Other sponsors include 407 different institutions and companies that sponsored additional 212 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Hillman Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 111 trials as a collaborator, "Merck Sharp & Dohme LLC" with 27 trials as a collaborator, "Bristol-Myers Squibb" with 23 trials as a collaborator, "Genentech, Inc." with 9 trials as a collaborator and "Cancer and Leukemia Group B" with 8 trials as a collaborator. Other collaborators include 207 different institutions and companies that were collaborators in the rest 134 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Hillman Cancer Center" are "Melanoma" (43 trials), "Breast Cancer" (33 trials), "Colorectal Cancer" (23 trials), "Lung Cancer" (20 trials) and "Prostate Cancer" (20 trials). Many other conditions were trialed in "UPMC Hillman Cancer Center" in a lesser frequency.

Most popular intervention types in "UPMC Hillman Cancer Center" are "Drug" (430 trials), "Biological" (115 trials), "Radiation" (47 trials), "Other" (44 trials) and "Procedure" (40 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (35 trials), "Pembrolizumab" (26 trials), "Nivolumab" (25 trials), "Gemcitabine" (22 trials) and "radiation therapy" (16 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Hillman Cancer Center" are 473 trials for "All" genders, 34 trials for "Female" genders and 25 trials for "Male" genders.

Currently, there are 205 active trials in "UPMC Hillman Cancer Center". 2 are not yet recruiting, 121 are recruiting, 80 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 219 completed trials in UPMC Hillman Cancer Center, 4 suspended trials, and 78 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Hillman Cancer Center, 193 "Phase 1" clinical trials were conducted, 269 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 18 trials that are defined as “Not Applicable".